Vaccines comprising an immunostimulatory peptide and an immunostimulatory oligodeoxynucleic acid molecule

Abstract

The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R 1 —XZSZ N —XZX—R 2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.

1 - 16 . (canceled) 
     
     
         17 . A method of improving an antigen-specific type 1 response of a vaccine against a viral pathogen and preserving or increasing a type 2 response of said vaccine comprising:
 obtaining a peptide comprising the sequence KLKL 5 KLK (SEQ ID NO: 6) and an I-ODN, wherein the I-ODN comprises oligo-d(IC) 13  (SEQ ID NO: 21); and   administering the peptide and the I-ODN with a vaccine against a viral pathogen to a subject;   
       wherein the antigen-specific type 1 response to the vaccine against a viral pathogen is improved in the subject and the type 2 response to the vaccine is preserved or increased in the subject. 
     
     
         18 . The method according to  claim 17  wherein the antigen-specific type 1 response is further defined as an IgG2-antibody response or an IFN-gamma response. 
     
     
         19 . The method according to  claim 17  wherein the type 2 response is further defined as an IgG1-antibody response or an interleukin-4 (IL-4) response. 
     
     
         20 . The method according to  claim 17  wherein the vaccine comprises a viral antigen. 
     
     
         21 . The method according to  claim 17  wherein the vaccine further comprises an Al(OH)3 adjuvant. 
     
     
         22 . The method according to  claim 20  wherein the viral antigen is derived from HIV, HAV, HBV, HCV, JEV, RSV, EBV, Influenza virus, HPV or Rotavirus. 
     
     
         23 . The method according to  claim 17  wherein the vaccine further comprises a polycationic peptide. 
     
     
         24 . The method according to  claim 17  wherein the vaccine further comprises an oligodeoxynucleotide containing a CpG-motif. 
     
     
         25 . The method according to  claim 17  wherein the vaccine further comprises a polycationic peptide and an oligodeoxynucleotide containing a CpG-motif. 
     
     
         26 . A method of improving an antigen-specific type 1 response of an immunogenic composition against a viral infection and preserving or increasing a type 2 response of said immunogenic composition comprising:
 obtaining a peptide comprising the sequence KLKL 5 KLK (SEQ ID NO: 6) and an I-ODN, wherein the I-ODN comprises oligo-d(IC) 13  (SEQ ID NO: 21); and   administering the peptide and the I-ODN with an immunogenic composition against a viral infection to a subject;   
       wherein the antigen-specific type 1 response to the immunogenic composition against a viral infection is improved in the subject and the type 2 response to the immunogenic composition is preserved or increased in the subject. 
     
     
         27 . The method according to  claim 26  wherein the antigen-specific type 1 response is further defined as an IgG2-antibody response or an IFN-gamma response. 
     
     
         28 . The method according to  claim 26  wherein the type 2 response is further defined as an IgG1-antibody response or an interleukin-4 (IL-4) response. 
     
     
         29 . The method according to  claim 26  wherein the immunogenic composition comprises a viral antigen. 
     
     
         30 . The method according to  claim 26  wherein the immunogenic composition further comprises an Al(OH)3 adjuvant. 
     
     
         31 . The method according to  claim 29  wherein the viral antigen is derived from HIV, HAV, HBV, HCV, JEV, RSV, EBV, Influenza virus, HPV or Rotavirus. 
     
     
         32 . The method according to  claim 26  wherein the immunogenic composition further comprises a polycationic peptide. 
     
     
         33 . The method according to  claim 26  wherein the immunogenic composition further comprises an oligodeoxynucleotide containing a CpG-motif. 
     
     
         34 . The method according to  claim 26  wherein the immunogenic composition further comprises a polycationic peptide and an oligodeoxynucleotide containing a CpG-motif.